Humana Inc. (NYSE:HUM) is included among the 14 Best GARP Stocks to Buy According to Analysts. Barclays Lowers Humana (HUM) Price Target amid Questions on Margin Expansion Outlook On February 25, Barclays lowered its price recommendation on Humana Inc. (NYSE:HUM) to $176 from $245. The firm reiterated an Equal Weight rating on the shares. It said it is “incrementally cautious” about the company’s expectation that Individual Medicare Advantage margins will double. A February 14 Bloomberg report said Huma ...

Centene Corporation (NYSE:CNC) is included among the 14 Best GARP Stocks to Buy According to Analysts. Truist Lifts Centene (CNC) Target to $49, Maintains Buy Rating After Positive Management Meetings On February 25, Truist raised its price recommendation on Centene Corporation (NYSE:CNC) to $49 from $47. The firm maintained a Buy rating on the shares. The analyst told investors that the firm remains bullish on the stock following positive meetings with management. Truist said it sees meaningful margin o ...

Tenet Healthcare Corporation (NYSE:THC) is one of the best strong buy healthcare stocks to invest in. Truist lifted the price target on Tenet Healthcare Corporation (NYSE:THC) to $270 from $240 on February 17 and maintained a Buy rating on the shares, telling investors that it adjusted its model after the company released its fiscal Q4 financial results and 2026 guidance. Tenet Healthcare Corporation (THC) Has Jim Cramer Seriously Worried Due To Medicaid Cutback Wells Fargo also lifted the price target o ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Ardent Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 9, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 9, 2026, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, claiming an active monitoring process that was not actually employed [5]. - Defendants reportedly downplayed increased claim denials by third-party payors and did not write off uncollectible accounts, which allowed them to report inflated accounts receivable [5]. - The firm also failed to maintain sufficient professional malpractice liability insurance, which was inadequate to cover claims arising from operations, particularly in the New Mexico market [5].

Financial Performance - Progyny reported revenue of $318.4 million for the quarter ended December 2025, reflecting a 6.7% increase year-over-year [1] - Earnings per share (EPS) for the quarter was $0.48, up from $0.42 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $303.93 million by 4.76% [1] - The company delivered an EPS surprise of 25.49%, with the consensus EPS estimate being $0.38 [1] Key Metrics - Utilization for female-only services was 0.5%, matching the two-analyst average estimate [4] - Average members reached 6,707, surpassing the two-analyst average estimate of 6,586 [4] - Revenue from pharmacy benefit services was $109.8 million, slightly below the estimated $110.78 million, representing a year-over-year decrease of 1.1% [4] - Revenue from fertility benefit services was $208.6 million, exceeding the three-analyst average estimate of $192.06 million, with a year-over-year increase of 11.3% [4] Stock Performance - Progyny's shares have returned -13.1% over the past month, while the Zacks S&P 500 composite has increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Progyny (NasdaqGS:PGNY) Q4 2025 Earnings call February 26, 2026 04:45 PM ET Company ParticipantsJames Hart - VP of Investor RelationsMark Livingston - CFOPete Anevski - CEOSarah James - Managing DirectorConference Call ParticipantsBrian Tanquilut - Equity Research AnalystConstantine Davides - Healthcare Services AnalystJailendra Singh - Managing Director and Equity Research AnalystMichael Cherny - Senior Managing Director and Senior Research AnalystPeter Warendorf - Equity Research AnalystScott Schoenhaus - ...

Progyny (NasdaqGS:PGNY) Q4 2025 Earnings call February 26, 2026 04:45 PM ET Company ParticipantsJames Hart - VP of Investor RelationsMark Livingston - CFOPete Anevski - CEOSarah James - Managing DirectorConference Call ParticipantsBrian Tanquilut - Equity Research AnalystConstantine Davides - Healthcare Services AnalystJailendra Singh - Managing Director and Equity Research AnalystMichael Cherny - Senior Managing Director and Senior Research AnalystPeter Warendorf - Equity Research AnalystScott Schoenhaus - ...

Evolent to Participate in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationWASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences.A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor r ...

Key Takeaways Teladoc Health reported a Q4 adjusted loss of 14 cents, narrower than estimates and year-ago loss.TDOC saw 19% international growth and 5% Integrated Care revenue growth, boosting results.BetterHelp revenues fell 6% in Q4, with 2026 guidance projecting further declines in the segment.Teladoc Health, Inc. (TDOC) reported a fourth-quarter 2025 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents. The company posted a loss of 28 cents in the year-a ...

Performance was driven by a diversified value-based platform serving over 1.5 million patients across 130 commercial and government programs, reducing dependency on any single contract. Management attributed strong EBITDA growth to significant operating leverage on cost of platform and G&A expenses, reaching a 27.2% EBITDA margin as a percentage of care margin. High gross provider retention of 98% and strong new provider implementations provided visibility into 2026, despite a difficult healthcare ser ...